Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,403 across all filing types
Latest filing 2019-02-01 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TOTAL VOTING RIGHTS
Regulatory Filings
2019-02-01 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is explicitly marked with an 'RNS Number' and states that the information is provided by RNS, the news service of the London Stock Exchange, approved by the FCA. The content details the total number of voting rights and issued share capital as of a specific date (January 31, 2019), which is a regulatory disclosure required under the Disclosure and Transparency Rules. This type of mandatory, short-form regulatory announcement that doesn't fit a more specific category (like DIRS or DIV) is best classified as a general Regulatory Filing, or RNS, as indicated by the source.
2019-02-01 English
FORXIGA RECEIVES POSITIVE EU CHMP OPINION
Regulatory Filings
2019-02-01 English
Forxiga receives positive EU CHMP opinion
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 8703O' and is dated February 1, 2019. It announces a positive opinion from the EU CHMP (Committee for Medicinal Products for Human Use) regarding the drug Forxiga for type-1 diabetes treatment. This is a specific, time-sensitive announcement related to regulatory/medical news, distributed via RNS (Regulatory News Service). Since it is a specific regulatory/medical update that doesn't fit into the defined categories like ER, AR, or LTR, and it is clearly distributed through the RNS system, the most appropriate classification is the general regulatory announcement fallback, RNS. It is not a full report (like 10-K or IR) nor a management change or dividend notice.
2019-02-01 English
SC 13G
Major Shareholding Notification
2019-01-30 English
COMPLETION OF DIVESTMENT OF US SYNAGIS RIGHTS
Regulatory Filings
2019-01-25 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.